Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

December 10, 2023

https://www.globenewswire.com/news-release/2023/12/09/2793443/0/en/Cogent-Biosciences-Announces-Positive-Initial-Data-from-Phase-2-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-Nonadvanced-Systemic-Mastocytosis-NonAdvSM.html

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20

Read more at globenewswire.com

Related news for (COGT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.